NuCana plc (NASDAQ:NCNA) Short Interest Update

NuCana plc (NASDAQ:NCNA) was the recipient of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 9,300 shares, a decrease of 94.4% from the March 31st total of 164,900 shares. Approximately 0.5% of the shares of the stock are short sold. Based on an average trading volume of 70,700 shares, the short-interest ratio is presently 0.1 days.

NuCana Price Performance

NASDAQ:NCNA remained flat at $3.84 during trading hours on Thursday. The company’s stock had a trading volume of 16,490 shares, compared to its average volume of 58,149. The business has a 50 day simple moving average of $7.02 and a 200-day simple moving average of $8.85. NuCana has a 52-week low of $3.40 and a 52-week high of $23.75. The firm has a market cap of $8.03 million, a price-to-earnings ratio of -0.24 and a beta of 0.92.

NuCana (NASDAQ:NCNA) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($4.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.25) by ($1.00). As a group, equities research analysts predict that NuCana will post -12.06 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Oppenheimer reiterated an “outperform” rating and issued a $100.00 price target on shares of NuCana in a research report on Monday, April 1st.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.